Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 3
1988 6
1989 10
1990 6
1991 12
1992 11
1993 18
1994 13
1995 22
1996 30
1997 35
1998 41
1999 41
2000 53
2001 57
2002 44
2003 39
2004 57
2005 60
2006 83
2007 71
2008 75
2009 80
2010 99
2011 93
2012 109
2013 144
2014 159
2015 196
2016 186
2017 193
2018 222
2019 204
2020 230
2021 278
2022 102
Text availability
Article attribute
Article type
Publication date

Search Results

2,713 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
The neuropathological diagnosis of Alzheimer's disease.
DeTure MA, Dickson DW. DeTure MA, et al. Mol Neurodegener. 2019 Aug 2;14(1):32. doi: 10.1186/s13024-019-0333-5. Mol Neurodegener. 2019. PMID: 31375134 Free PMC article. Review.
Alzheimer's disease is the most common cause of dementia globally. ...Other disease processes that are frequent, but not inevitable, are also discussed, including pathologic processes that can clinically mimic Alzheimer's disease.
Alzheimer's disease is the most common cause of dementia globally. ...Other disease processes that are frequent,
Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.
Thal DR, Walter J, Saido TC, Fändrich M. Thal DR, et al. Acta Neuropathol. 2015 Feb;129(2):167-82. doi: 10.1007/s00401-014-1375-y. Epub 2014 Dec 23. Acta Neuropathol. 2015. PMID: 25534025 Review.
Alzheimer's disease (AD) is characterized by beta-amyloid plaques and intraneuronal tau aggregation usually associated with cerebral amyloid angiopathy (CAA). ...Thus, the inhibition of Abeta aggregation and maturation before entering the symptomatic stage of
Alzheimer's disease (AD) is characterized by beta-amyloid plaques and intraneuronal tau aggregation usually associated
Early- and late-onset Alzheimer disease: Are they the same entity?
Tellechea P, Pujol N, Esteve-Belloch P, Echeveste B, García-Eulate MR, Arbizu J, Riverol M. Tellechea P, et al. Neurologia (Engl Ed). 2018 May;33(4):244-253. doi: 10.1016/j.nrl.2015.08.002. Epub 2015 Nov 3. Neurologia (Engl Ed). 2018. PMID: 26546285 Free article. Review. English, Spanish.
Early-onset Alzheimer disease (EOAD), which presents in patients younger than 65 years, has frequently been described as having different features from those of late-onset Alzheimer disease (LOAD). ...Fundamentally, the onset of EOAD is more likely to …
Early-onset Alzheimer disease (EOAD), which presents in patients younger than 65 years, has frequently been described as havin …
Molecular mechanisms of neuropathological changes in Alzheimer's disease: a review.
Serý O, Povová J, Míšek I, Pešák L, Janout V. Serý O, et al. Folia Neuropathol. 2013;51(1):1-9. doi: 10.5114/fn.2013.34190. Folia Neuropathol. 2013. PMID: 23553131 Free article. Review.
More than 100 years after description of Alzheimer's disease (AD), two major pathological processes observed already by Alois Alzheimer, remain as the main explanation of the pathogenesis of Alzheimer's disease. ...Promising explan …
More than 100 years after description of Alzheimer's disease (AD), two major pathological processes observed already by …
The neuropathology of chronic traumatic encephalopathy.
McKee AC, Stein TD, Kiernan PT, Alvarez VE. McKee AC, et al. Brain Pathol. 2015 May;25(3):350-64. doi: 10.1111/bpa.12248. Brain Pathol. 2015. PMID: 25904048 Free PMC article. Review.
Given the importance of sports participation and physical exercise to physical and psychological health as well as disease resilience, it is critical to identify the genetic risk factors for CTE as well as to understand how other variables, such as stress, age at ex …
Given the importance of sports participation and physical exercise to physical and psychological health as well as disease resilience …
Aging and Alzheimer's disease pathology.
Sengoku R. Sengoku R. Neuropathology. 2020 Feb;40(1):22-29. doi: 10.1111/neup.12626. Epub 2019 Dec 21. Neuropathology. 2020. PMID: 31863504 Review.
When studying dementia, understanding the basis of the neuropathological background is very important. Taking Alzheimer's disease (AD) neuropathology as an example, we know that the accumulation of abnormal structures such as senile plaques and neurofi …
When studying dementia, understanding the basis of the neuropathological background is very important. Taking Alzheimer's d
Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors.
Lagomarsino VN, Pearse RV 2nd, Liu L, Hsieh YC, Fernandez MA, Vinton EA, Paull D, Felsky D, Tasaki S, Gaiteri C, Vardarajan B, Lee H, Muratore CR, Benoit CR, Chou V, Fancher SB, He A, Merchant JP, Duong DM, Martinez H, Zhou M, Bah F, Vicent MA, Stricker JMS, Xu J, Dammer EB, Levey AI, Chibnik LB, Menon V, Seyfried NT, De Jager PL, Noggle S, Selkoe DJ, Bennett DA, Young-Pearse TL. Lagomarsino VN, et al. Neuron. 2021 Nov 3;109(21):3402-3420.e9. doi: 10.1016/j.neuron.2021.08.003. Epub 2021 Sep 1. Neuron. 2021. PMID: 34473944
We have generated a controlled and manipulable resource that captures genetic risk for Alzheimer's disease: iPSC lines from 53 individuals coupled with RNA and proteomic profiling of both iPSC-derived neurons and brain tissue of the same individuals. D …
We have generated a controlled and manipulable resource that captures genetic risk for Alzheimer's disease: iPSC …
Epigenetics of Alzheimer's Disease.
Nikolac Perkovic M, Videtic Paska A, Konjevod M, Kouter K, Svob Strac D, Nedic Erjavec G, Pivac N. Nikolac Perkovic M, et al. Biomolecules. 2021 Jan 30;11(2):195. doi: 10.3390/biom11020195. Biomolecules. 2021. PMID: 33573255 Free PMC article. Review.
There are currently no validated biomarkers which can be used to accurately diagnose Alzheimer's disease (AD) or to distinguish it from other dementia-causing neuropathologies. ...The aim of the article was to provide a brief overview of the current kn …
There are currently no validated biomarkers which can be used to accurately diagnose Alzheimer's disease (AD) or to dis …
Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease.
Li X, Tsolis KC, Koper MJ, Ronisz A, Ospitalieri S, von Arnim CAF, Vandenberghe R, Tousseyn T, Scheuerle A, Economou A, Carpentier S, Otto M, Thal DR. Li X, et al. Alzheimers Dement. 2021 Jun;17(6):946-958. doi: 10.1002/alz.12345. Epub 2021 Apr 19. Alzheimers Dement. 2021. PMID: 33871169
Proteome profile changes in Alzheimer's disease (AD) brains have been reported. However, it is unclear whether they represent a continuous process, or whether there is a sequential involvement of distinct proteins. ...
Proteome profile changes in Alzheimer's disease (AD) brains have been reported. However, it is unclear whether they rep …
Early-Onset Alzheimer's Disease: What Is Missing in Research?
Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C. Ayodele T, et al. Curr Neurol Neurosci Rep. 2021 Jan 19;21(2):4. doi: 10.1007/s11910-020-01090-y. Curr Neurol Neurosci Rep. 2021. PMID: 33464407 Free PMC article. Review.
PURPOSE OF REVIEW: Early-onset Alzheimer's disease (EOAD), defined as Alzheimer's disease (AD) occurring before age 65, is significantly less well studied than the late-onset form (LOAD) despite EOAD often presenting with a more aggressiv …
PURPOSE OF REVIEW: Early-onset Alzheimer's disease (EOAD), defined as Alzheimer's disease (AD) occ …
2,713 results